AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition

Strategies to find targets in patient data are largely grounded in genetics, but the toolbox is diversifying, and increasingly longitudinal

Back to School 2023 case study: Regeneron’s is a story of leveraging platform technology to repeatedly generate high-value assets

Supreme Court decision puts an end to antibody genus claims. It could hurt more differentiated innovation

Antitrust agency making good on promise to use untested theories to block pharma M&A

Oral arguments in the SCOTUS Amgen v. Sanofi case lean into its impact on innovation

The pharma sunk $325M into vupanorsen, but won’t get its ‘mega-blockbuster’ in cardiovascular indications

Can twice-yearly injectable cholesterol-lowering therapy succeed where other drugs against the target have struggled?

Plus Selecta’s clinical hold, Allorion’s fund-raising and a Philogen-Janssen deal

BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) are preparing to submit a BLA to FDA for the partners’ COVID-19 vaccine after reporting six-month efficacy data